Domov › Trojnásobne negatívny karcinóm prsníka › Massachusetts
Klinické štúdie Trojnásobne negatívny karcinóm prsníka v štáte Massachusetts
26 štúdií pre Trojnásobne negatívny karcinóm prsníka hľadá účastníkov v zariadeniach v štáte Massachusetts.
Mestá v štáte Massachusetts
Oficiálny text štúdie (anglicky)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 12 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT04585750A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06465069A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 19 a viac · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT06586957Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT05422794A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06966700Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 9. 2026 · NCT05983432A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
- Massachusetts General Hospital, Boston
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT07513311First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 9. 2026 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
- a 4 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT05633654A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 8. 2026 · NCT07029399A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT07182149Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 8. 2026 · NCT07341867A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 8. 2026 · NCT06926868DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 6. 8. 2026 · NCT06176261Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 8. 2026 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 až 100 · Všetky pohlavia · Aktualizované 29. 7. 2026 · NCT06562192A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT06150664Sacituzumab Govitecan In TNBC
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
- Massachusetts General Hospital - North Shore Cancer Center, Danvers
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 7. 2026 · NCT04230109Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 13. 7. 2026 · NCT07137416A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT05377996A Study of LY4175408 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 6. 2026 · NCT07046923Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- Dana-Farber Cancer Institute, Boston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 4. 5. 2026 · NCT04434040Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Dana Farber Cancer Institute, Boston
- DFCI @ Foxborough, Foxborough
- DFCI @ Milford Regional Hospital, Milford
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 4. 2026 · NCT04468061This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 4. 2026 · NCT06451497A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 17. 3. 2026 · NCT06908928Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 11. 2024 · NCT04787042Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.